Electromyographic Response of Healthy Muscle Following the Induction of Capsaicin

Valerie Evans, MA Sc (C)\textsuperscript{1,2}, B.Eng; Kei Masani, PhD, MEd, BEd\textsuperscript{2,3}; Dinesh Kumbhare, MD, PhD, FRCPC, FAAPMR\textsuperscript{1,2,3}

\textsuperscript{1}Department of Medicine, Division of Physical Medicine and Rehabilitation, University of Toronto, Toronto, Ontario, Canada
\textsuperscript{2}Institute of Biomaterials and Biomedical Engineering (IBBME), University of Toronto, Toronto, Ontario, Canada
\textsuperscript{3}Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario, Canada

Date: May 6, 2019

Corresponding Author:
Dinesh Kumbhare, MD, PhD, FRCPC, FRCPC, FAAPMR
Associate Professor, Department of Medicine
Division of Physical Medicine and Rehabilitation
University of Toronto
Toronto Rehabilitation Institute
550 University Ave.
Toronto, ON M5G 2A2
P: 416-597-3422 x 4612
Email: dinesh.kumbhare@uhn.ca
Abstract

Background: Myofascial pain syndrome (MPS) is a prevalent chronic pain disorder primarily characterized by myofascial trigger points (MTrP). There is limited knowledge on the pathophysiology and mechanisms underlying MTrP and its development. Electromyography (EMG) investigations of MTrP have demonstrated that MTrP are usually located proximal to innervation zones where the peak surface EMG signals are obtained from. Central sensitization has been proposed as the primary mechanism underlying MTrP development. Central sensitization is associated with hyperexcitability of neuronal responses to normal or noxious stimuli. There is a need for a study that measures specific motor unit activity responses in the muscle following sensitization. The purpose of this study is to determine whether sensitizing healthy muscle using capsaicin induces a change in motor unit frequency and amplitudes that are specific to MTrPs. This concept has yet to be investigated. This is an exploratory trial that aims to provide preliminary evidence on whether central sensitization is a direct cause of taut band and MTrP development.

Methods: The study conforms to the Consolidated Standards of Reporting Trials recommendations. Ethical approval will be sought from the University Health Network (UHN) Research Ethics Board. This proposed study is a single centered, factorial, randomized placebo-controlled trial with two independent variables, depth of capsaicin application and dose of capsaicin, for a total of four treatment arms and two control treatment groups.

Discussion: This will be the first study that assesses the effect of stimulus induced central sensitization on muscle motor unit activity. Findings from this study may support one of few hypotheses proposed delineating the involvement of central sensitization in the development of
trigger points. Overall, the findings from this study should present preliminary evidence to inform central sensitization’s effects on motor unit activity.

Trial registration: This study will be registered under the National Institutes of Health ClinicalTrials.gov.

**Keywords:** myofascial pain syndrome; electromyography; central sensitization; trigger points
List of Abbreviations:

EMG: Electromyography

MPS: Myofascial pain syndrome

MTrP: Myofascial trigger points

SEA: Spontaneous endplate activity
Background

Myofascial pain syndrome (MPS) is a prevalent chronic pain disorder primarily characterized by myofascial trigger points (MTrP). MTrP are stiff taut bands of muscle distinguished by hypersensitivity on palpation and local twitch responses on snapping palpation.[1] A current clinical challenge in chronic pain care, applicable to myofascial pain, is early detection and effective treatment targeting the underlying pathophysiology.

There is limited knowledge on the pathophysiology and mechanisms underlying MTrP and its development. Some characteristics of MTrP have been elucidated. Trigger points are typically located within the region of the muscle belly, where there is a high distribution of motor endplates.[2,3] Seventy-one percent of acupoint locations in the body, which are regions associated with motor points, motor endplates, or major motor nerve pathways overlap with common MTrP.[4] Electromyography (EMG) investigations of MTrP have demonstrated that MTrP are usually located proximal to innervation zones where the peak surface EMG signals are obtained from.[3] Motor endplates at MTrP present with spontaneous endplate activity (SEA) associated with excessive acetylcholine release.[5,6] In latent and active trigger points, SEA is characterized by continuous low amplitude action potentials. Active MTrP, which are more painful clinically, elicit intermittent spikes in addition to SEA. This continuous activity is thought to overexert and hyper-contract the muscle resulting in the presentation of a taut band.[7] Studies assessing the contractility of MTrP have found increased muscle fatigability in active and latent MTrP relative to unaffected muscles. Furthermore, it has also been demonstrated that there is increased fatigability and EMG activity in active MTrP relative to latent ones.[8] This data suggests that perturbations in the efferent system involved in muscle control is a vital component of the MTrP pathophysiology.
Central sensitization has been proposed as the primary mechanism underlying MTrP development. Central sensitization is associated with hyperexcitability of neuronal responses to normal or noxious stimuli.[9] Furthermore, this concept offers an explanation of the afferent, efferent and abnormal signal modulation at the spinal cord level.[9,10] Patients with myofascial pain present with hyperalgesia and decreased pain threshold, i.e., signs of central sensitization, particularly at the region of MTrP.[5,11] Experimental evidence has demonstrated that afferent nociceptive fibers at the region of MTrP are sensitized. Neurons in the dorsal horn segment corresponding to the location of MTrP are also sensitized, manifesting clinically as hyperalgesia within the dermatome affected by MTrP.[12] This is evidenced by Kim et al’s[12] findings whereby they reported transcutaneous electric stimulation increased MTrP pressure pain thresholds when applied at a remote region within the same dermatome. Srbley et al.[1] further presented evidence of a sensitization arc that maintains the MTrP contracture. They experimentally induced sensitization at a remote region in the dermatome wherein a latent MTrP is located using topical capsaicin, and subsequently found a decrease in pressure pain thresholds at the MTrP.

Investigations assessing neuronal responsivity to noxious stimuli have demonstrated increased sensitization at the region of primary nociception and the development of a secondary nociceptive field.[13-15] This has been confirmed using EMG and quantitative sensory testing methods to assess the activity of sensory nociceptive, mechanoheat, and chemoreceptive nerve fibers following the injection or application of capsaicin.[13-15] Studies have yet to assess the effect of nociception on segmentally innervated motor neurons. Dideriksen et al.[16] and Falla et al.[17] demonstrated that motor unit potentials reduce in amplitude following the injection of nociceptive hypertonic saline into the upper trapezius muscle. This is in line with the EMG
characteristics of MTrPs cited earlier.[7,8] However, discharge patterns decreased on injection with hypertonic saline in some motor units and increased in others unlike the continuous discharge pattern observed at MTrPs. These studies cannot be translated to the chronic pain patient since they provide evidence for experimentally induced sensitization using capsaicin. Many other factors are likely involved in the chronic pain patient including disordered ascending and descending signals within the central nervous system.[18,19] Additionally, they utilized surface EMG which does not capture specific motor unit activity affected by neighboring signals. Studies assessing the EMG activity of trigger points failed to locate the aberrant activity that characterizes MTrP using surface EMG but were able to demonstrate the presence of SEA, intermittent spikes in active MTrP, as well as activity associated with local twitch responses using intramuscular EMG recordings due to the method’s specificity.[5] There is a need for a study that measures specific motor unit activity responses in the muscle following sensitization.

The purpose of this study is to determine whether sensitizing healthy muscle using capsaicin induces a change in motor unit frequency and amplitudes that are specific to MTrPs. This concept has yet to be investigated in the literature based on a systematic search of two prominent databases, Medline and EMBASE as of May 2018. Central sensitization will be induced using topical capsaicin and injectable capsaicin at three different concentrations. This is an exploratory trial that aims to provide preliminary evidence on whether central sensitization is a direct cause of taut band and MTrP development.

Our specific research questions are followings:

a. Does capsaicin induced sensitization elicit a change in motor unit action potential(MUAP) amplitude by approximately 20 to 25%, as observed in studies inducing muscle nociception by Diderkriksen et al.[16] and Falla et al.[17]. Our hypothesis for this
portion of the study is that sensitization modifies the anterior horn cell activity which we will measure by the amplitude of the potentials. The population of anterior horn cells that are activated when sensitized is altered.

b. Does capsaicin induced sensitization elicit continuous electrical activity as observed in MTrPs? This tests the hypothesis that sensitization creates the presence of continuous low amplitude action potentials.

c. Does capsaicin induced sensitization influence the rate of recruitment of motor units in the muscle? The recruitment of motor units is normally expected to follow the Henneman size principle.[20-23] Our hypothesis for this portion of the study is that sensitization will cause an aberration in recruitment. If we are able to demonstrate this then we can postulate that there is modification of the normal processing at both dorsal and ventral horns of the spinal cord.

d. Is there a location dependent EMG response to capsaicin induced sensitization? In other words, do motor units that lie anatomically distant from the location of the site of intramuscular capsaicin injection have different rates of recruitment and amplitude than those that are anatomically located very close to the site of injection? This would test the hypothesis that type III and IV afferents have an influence on the anterior horn cells that lie distant to the ones that are supplying muscle fibers in the vicinity of the stimulated sensory afferents.

e. Is there a dose dependent EMG response at motor units to capsaicin induced sensitization? Here, the hypothesis of causality will be assessed in a preliminary manner. If we are able to show a relationship then we plan to design further experiments that more thoroughly assess causality.
Methods & Design

Study Design:

The study conforms to the Consolidated Standards of Reporting Trials recommendations. Ethical approval will be sought from the University Health Network (UHN) Research Ethics Board. This study will be registered under the National Institutes of Health ClinicalTrials.gov.

This proposed study is a single centered, factorial, randomized placebo-controlled trial with two independent variables, depth of capsaicin application and dose of capsaicin, for a total of four treatment arms and two control treatment groups. The first between groups variable will be topical capsaicin application and injectable capsaicin injection. Within each partition there will be three treatments: control, 50 micrograms, 100 micrograms. One-hundred micrograms reported to be an effective high dose of capsaicin.[13] The control group will receive a topical skin lotion which is inert and has no sensitization effect. An equal number of participants will be allocated to each of the six treatment groups using an electronic randomization generator. Block randomization will be used to ensure equal allotment into each group. An alternate member of the research team will conduct the randomization schedule a priori. Participant allocation will be concealed by placing their assignment in an envelope and delivered to participants by the same member of the research team uninvolved in the measurement or randomization protocols.

Participants and investigators will be blinded to the delivered dose; however, the type of capsaicin delivery cannot be blinded from either participants or investigators. The member of the research team conducting the randomization schedule and concealing allocation will have knowledge of and keep track of the doses contained in the containers and vials of the topical and injectable capsaicin, respectively. They will deliver the appropriate dose to the team member
implementing the experimental protocol to ensure there is blinding with respect to dose. This individual will not be involved in participant recruitment.

Participants

Recruitment

Participants will be recruited from UHN and the University of Toronto clinics, employees, volunteers, visitors, students, and external participants. UHN is a tertiary healthcare centre with eight hospitals located in Toronto, Canada and the University of Toronto is an academic institution with a main campus located in close proximity to the main UHN hospitals in Toronto. Advertisements, flyers, and in person recruitment will be employed to collect the necessary sample size for the study. The recruitment procedures will run in line with the approved guidelines from the UHN research ethics boards. Participants will not be coerced into participating and will be informed that they have the right to withdraw at any time during the experimental procedures. They will also be informed they have the right to withdraw their data prior to publication. Participants will be briefed and consented on recruitment prior to commencing the study procedures. Participant treatment allocation will be recorded on a separate document until all of the data collection is complete and the data is analyzed.

Eligibility Criteria

Female or male participants who meet the following inclusion criteria will be included in the study: (1) participants are healthy with no past medical history (2) a visual analogue score below 3 indicating low pain severity, however, ideally who complain of no pain (3) right or left handed, (4) normal body mass index, (5) have sufficient command of the English language to
provide informed consent and to understand the study protocols, (6) participants agree to sign a consent to volunteer for the research.

**Exclusion Criteria**

Participants who meet one or more of the following criteria will be excluded: (1) history of pain, (2) physical examination detection of myofascial trigger points, (3) participants present with a history of pain related disturbances such as poor sleep, cognitive disturbances, psychiatric disorders, (4) history of general medical disorder that may affect the outcome of the study such as diabetes mellitus, (5) and a history of cervical radiculopathies or (6) history of inflammatory arthropathy.

**Experimental Protocol**

This experimental protocol will be carried out at the Kumbhare Lab, Toronto Rehabilitation Institute to ensure any medical emergencies can be promptly cared for. Following the completion of the preliminary intake forms and participant debriefing, informed consent will be obtained. Each participant will be seated upright with their hands comfortably on their lap in a chair that has a high supportive back. They will be asked to relax their neck and shoulder muscles. A member of the research team will then apply the inclusion and exclusion criteria. The presence of a MTrP will be assessed by palpation of the upper trapezius muscle since this is the current method utilized in clinical practice. If there is a MTrP, then they will be asked to withdraw from the study since they do not satisfy the inclusion and exclusion criteria.

Participants will sit on a chair with one arm extended downward, and with the other arm on an armrest of the chair. The extended arm will be fixed by a wristcuff and a chain down to the floor, with a loadcell between the floor and the end of chain. The loadcell will measure the exerted force. Participants will be asked to gently contract their trapezius muscle. They will be
instructed to perform a gradually increasing contraction in isometric condition, in a controlled manner with a monitor showing the exerted force as well as the target force. They will hold this contraction at 30% of their maximal voluntary contraction, and then perform a gradually decreasing contraction to rest. This will be performed four times for each type of study intervention and before as well as after each intervention, namely topical control cream, topical capsaicin at 50 ug and 100 ug, injection of the superior aspect of the superior fascia followed by intramuscular injection with these two concentrations of capsaicin. The placement of these latter will be verified by ultrasound guidance. The intramuscular needle will then be removed and participants will be bandaged and cared for appropriately by the expert physician performing the experiment. Participants will be re-examined to determine if there were any adverse effects from the experimental procedures. If any occurred, then these will be carefully managed by the medical members of the research team and recorded. Participants will be asked to remain at the lab for an additional 30 minutes to ensure they are well prior to leaving (Figure 2).

Central sensitization and measurement techniques

*Inducing central sensitization*

Central sensitization will be induced using capsaicin according to the established technique.[13,24,25] It induces increased pain severity at high doses relative to heat and elicits a dose dependent pain responses, allowing for more easily quantifiable measurements.[26] Capsaicin delivery induces both primary and secondary nociception suggesting that central mechanisms are involved in the nociceptive response, also termed as central sensitization.[13,14] Previous evidence has confirmed that capsaicin can sensitize nociceptive and mechanoheat receptors outside of the region of primary hyperalgesia, with speculation that it can also sensitize
chemonociceptive receptors.[13] Therefore, capsaicin can effectively be used to induce central sensitization.

Capsaicin will be applied directly to the region of the innervation zone at the muscle belly to sensitize the neurons within the region of taut band development. Topical and intramuscular capsaicin will be used. The capsaicin formula will be compounded by a registered pharmacist. Topical capsaicin will be delivered in a cream and injectable capsaicin will be intermixed with saline prior to injection. The control group in the topical capsaicin arm will be treated with the cream base used during the experiment without added capsaicin and the injection arm will be injected with saline. A trained medical professional on the research team will apply the topical capsaicin or topical placebo treatments. The region of topical application will measure 5cm squared in the dermatome zone location to cover an area of approximately 25cm$^2$. A trained physician in physical medicine and rehabilitation will deliver injectable capsaicin using a 27-gauge needle at the location of the superior fascia of the upper trapezius muscle with ultrasound guidance. The fascial layer was chosen as it is the region with the lowest pressure pain threshold relative to skin and muscle, suggesting a high density of nociceptors within the layer, and it possesses connections to the spinal cord.[27] Changes in muscle fascia properties and nociception at muscle fascia, compared to nociception at muscle or subcutaneous tissue, has also been implicated in the development of pain.[28,29] Furthermore, intramuscular capsaicin will also be injected using ultrasound guidance to avoid the superior or inferior fascia.

To confirm the presence of central sensitization, brush allodynia will be used to detect mechanical hyperalgesia outside the region of primary nociception—region of topical placement or injection—which is the region of secondary hyperalgesia.[13-15] The size of the region of secondary hyperalgesia will be measured to characterize the extent of central sensitization. This
will be accomplished using a tape measure and the perpendicular dimensions of the region of secondary hyperalgesia will be recorded in square centimeters.

*Measurement of motor unit activity using EMG*

The Delsys Trigno Galileo surface EMG system will be used in this experiment. The system offers the benefit of having a 4-pin mini-grid sensor that can extract individual motor unit data, without causing participants discomfort. The analysis will also be complemented by the use of intramuscular EMG, since it offers high location specificity when measuring EMG activity, while only a local region is analyzed. The intramuscular EMG data will be analyzed by a Cadwell Sierra Wave device.

The anatomical location for electrode placement, along the C7-acromion line, will be identified for each participant. Baseline EMG measurements will be taken from the upper trapezius muscle to obtain the baseline motor unit recruitment curve. The trapezius muscle was chosen for study since it is a common site for MTrPs, given the high load cervical muscles carry as well as the general increase sedentariness that perpetuates poor posture and cervical muscle strain, leading to trigger point presentation. Furthermore, the trapezius muscle has been used frequently in previously published work, which analyze motor unit parameters, power spectrum and amplitude measurements.[31,32,33]

*sEMG Analysis*

After the identification for electrode placement, the area will be cleaned with alcohol and water. The Delsys Galelio sensor will be placed directly on the identified area. The EMG sensor (bandwidth of 20-450Hz ) consists of 4 metal contacts for detecting the signal at the skin surface. Both the right and left sides of the trapezius will be measured.
The Delsys GalileoTrigno system, which includes sensors, the Trigno base station, and the EMGworks software will be used to decompose the acquired EMG signals into individual motor units. The following parameters will be analyzed: the firing times and frequency of individual motor units, motor unit action potential amplitude and shapes\[36-38\], the root mean square value (RMS) of each channel and of the entire signal\[16\], the coefficient of variation for force steadiness\[39\], and the centroid of the EMG signal in the cranial-caudal and the medial-lateral directions\[16\]. These procedures will be repeated for each contraction.

\textit{Intramuscular EMG Placement and analysis}

A 27g monopolar electromyography needle will be placed into the midbelly of the upper fibers of the trapezius muscle using ultrasound guidance. The intramuscular EMG signals will be measured using Cadwell Sierra Wave. Since this system does not offer motor unit decomposition, we will use the intramuscular EMG analysis to provide us with more details of the gross EMG measurements such as the overall RMS value, the coefficient of variation for force steadiness, and the centroid measurements.

Determination of Central Sensitization:

Before measuring outcomes, approximately 20 minutes after capsaicin application we will analyze the area of secondary hyperalgesia for each study subject, then determine whether central sensitization has in fact been induced. The presence of central sensitization is confirmed by expansion of the receptive field and area of secondary hyperalgesia beyond the 25 cm\(^2\) initial application area. If it has, the study participant will undergo the rest of the experimental methodology. If it has not, the capsaicin will be applied once more and the region of secondary hyperalgesia will be remeasured in 20 minutes later. The above described process for confirming
the presence of central sensitization will take place again. If the study participant has not had sensitization at this stage they will be withdrawn from the study.

*Primary Outcomes*

The primary outcome measures for each motor unit are:

1. Recruitment rate (Hz)
2. Amplitude (mV)

These will be recorded for each arm of the study, please see figure 1.

**Secondary outcomes:**

1. A record of adverse events
2. Safety evaluation

   The investigating physician monitors the patient clinically for signs of distress. The methods and timing for assessing, recording, and analyzing safety parameters. Any signs of distress noted by investigating physician will be assessed clinically and appropriately managed. The information will be recorded on the patient’s data form. The study team will discuss all incidents and any potential causal link to the study interventions. Patients will be provided with a contact number for the principal investigator in order to report any changes that occur during or after the study. Our publication will include a list of any adverse events or intercurrent illness encountered. Any patient who experiences an adverse event will be triaged to their family physician or local emergency department as necessary. They will be contacted after to obtain information on the course of their treatment and the outcome of the event.
3. Sample size calculation.
Using GPower V3.0.10 (Dusseldorf, Germany), considering a medium effect size (Hedge’s G) of 0.5 and a moderate correlation coefficients (0.5) among repeated measures, sample size calculation determined that a minimum of 70 participants would be required to detect differences via repeated measures ANOVA (two measurement as before and after among 7 groups) with 80% power and an alpha of 0.05. We aim to recruit 84 participants to account for potential attrition (~20%) of participants given the study duration and frequency of follow-up visits.

We plan to recruit equal number of men and women. To date, there are no reported sex differences in induction of Central Sensitization using Capsaicin among males and females with neurological impairments.

4. Statistical analysis plan
   Baseline participants’ characteristics including demographics will be analyzed using appropriate descriptive statistics. Mean and standard deviation will be calculated for continuous variables. Categorical variables will be presented as numbers and percentages. To test the change in EMG within and between groups a repeated measurement ANOVA will be applied considering each intervention group as factor. The dependent variable would be considered as pain intensity, duration, and area of pain in separate analysis. Data distributions would be first checked with the Shapiro-Wilk to conform the normal distribution of the data. Additionally, we will test for the homogeneity of variance using Mauchly’s test as well as correcting the degrees of freedom if necessary [40]. If the assumption of normality not met, for all skewed data an appropriate transformation will
be used. We will construct univariate and multivariable linear regression models of differences in EMG amplitude (differences between after and before) as a function of intervention groups when adjusted for important covariates. Due to small sample size in each group, there is not possible to adjust for several covariates. Therefore, in a univariate model we will find the most important ones. For initial selection of relevant variables, all variables with a p-value ≤ 0.2 in the univariate analysis will be selected and retained in the multivariable analysis.

All Statistical analyses will be conducted with SAS for Windows (version 9.3; SAS Institute, Inc, Cary, NC). Using a two-sided test a P-value ≤ 0.05 will be considered as statistically significant.

**Discussion**

This will be the first study that assesses the effect of capsaicin stimulus induced central sensitization on muscle motor unit activity. Findings from this study may support one of few hypotheses proposed delineating the involvement of central sensitization in the development of trigger points. A prominent hypothesis in the literature is the integrated hypothesis. The integrated hypothesis suggests that unaccustomed eccentric activity or submaximal to maximal concentric muscle exertion leads to muscle fiber damage, segmental hypercontraction within the muscle fibers, and ischemia. [6] The resultant damage and ischemia at the muscle instigates an inflammatory biomarker cascade that potentiates the activity of motor neurons, subsequently increasing the release of acetylcholine and inducing muscle contraction, and sensitizes sensory neurons. [6,41] The sensitization of peripheral sensory and motor neurons is thought to contribute to the sensitization of dorsal horn neurons in the associated spinal segment, which likely
influences efferent neuronal activity at the muscle. From this hypothesis, it would be expected to observe uncoordinated motor unit activity and activation given that muscle fiber damage has occurred and motor units may be differentially potentiated or sensitized. The findings from studies inducing acute nociception in the muscle support this hypothesis.[16,42] Hypertonic saline injections have been shown to reorganize muscle activity within the muscle.[42] Previous findings also suggest that motor unit discharge frequency changes variably among motor units, although predominantly decreasing, as a consequence of external nociception.[16] This study should elucidate whether a nociceptive stimulus that causes central sensitization induces uncoordinated motor unit activation and differential discharge patterns among the units. The integrated hypothesis presupposes that the cause of myofascial trigger points is exogenous and induces endogenous changes in muscle. The Cinderella and the neurogenic hypothesis suggest otherwise.

The Cinderella hypothesis suggests sustained low threshold motor unit activation metabolically overloads oxidative muscle fibers, leading to muscle fiber damage or ‘ragged fiber’ presentation and metabolic changes such as ischemia, hypoxia, and insufficient ATP.[7,41] This may result in disturbed calcium homeostasis and the development of the muscle contracture known as the trigger point. Low threshold motor unit activity was demonstrated in a number of articles assessing the effect of continued muscle contraction and psychologically demanding tasks—muscle overexertion and persistent psychological stress are theorized triggers for chronic pain and trigger point development.[43,44] The sustained contracture in the muscle maintains the hypoxic and acidic environment, leading to peripheral and central sensitization of neurons in the associated spinal segment.[7] This suggests an endogenous and exogenous cause for the trigger
points. Under the premise of the Cinderella hypothesis, it would be expected to observe sustained low threshold motor unit activity with central sensitization.

The neurogenic hypothesis is distinct from the integrated and Cinderella hypotheses as it poses trigger point development is a result of endogenous central sensitization.[1] Central sensitization would result from persistent nociceptive input from other peripheral mechanic or systemic pathologies leading to neurogenic inflammation, such as trauma or endocrine disease. Subsequently, inflammatory and algogenic substances would be released from peripheral nociceptors onto tissue and sensitizing the region. Sensitization of motor and sensory neurons innervating somatic muscle may lead to the phenomenon of trigger points. Ultimately, the neurogenic hypothesis stipulates the trigger point is a secondary outcome central sensitization, which is the primary pathology. Continuous low threshold motor unit activity would also be an anticipated observation as neurons will be increasingly sensitized. It would also be expected to observe increased low threshold motor unit activity in remote muscles that present with signs of central sensitization, e.g. hyperalgesia, however this is outside the scope of this article.

**Limitations and Conclusions**

Overall, the findings from this study should present preliminary evidence to inform central sensitization’s effects on motor unit activity. Results may provide plausibility for the aforementioned hypotheses. A limitation of this study is the degree of invasiveness needed to increase the specificity of the EMG measurements, however, the trade-off between invasiveness and specificity is necessary to ensure we capture a sufficient effect size with a feasible sample size. Additionally, the experimental protocol will be carried out on healthy participants with induced central sensitization to determine the effects of this phenomenon on muscle activity. Although these results are not directly generalizable to participants with myofascial pain, this
study’s results should provide insight as to whether central sensitization does perturb muscle activity, and inform further investigations into the pathophysiology of myofascial pain. Another limitation of this study in light of the integrated and Cinderella hypotheses is that sensitization will be induced prior to the assessment of EMG activity at motor neurons. However, it is important to understand whether central sensitization is a direct cause of aberrant motor unit activity, as a fraction of the population develops myofascial trigger points following precipitating events such as injury, stress, or poor posture. The presence of central sensitization at a specific severity or ‘tipping point’ may predispose some individuals to developing trigger points—or induce trigger points with increased severity—and the mechanisms described by the integrated or Cinderella hypotheses may lead to the manifestation of the trigger point. These hypotheses need not be mutually exclusive, but rather may be complementary or present as alternate etiologies to the development of the trigger point. It is possible the anatomical changes resulting from each hypothesis leads to a different manifestation of trigger points that appear clinically equal. Further studies assessing central sensitization markers and EMG activity of muscle innervated by spinal segments remote from the region of primary sensitization are needed to elucidate the overarching pathophysiology of trigger point presentation.

Acknowledgements: N/A
Declarations

*Ethics approval and consent to participate:

The study conforms to the Consolidated Standards of Reporting Trials recommendations. Informed consent will be obtained from all subjects participating in this study. Ethical approval was approved by the University Health Network (UHN) Research Ethics Board. The approval form is included in the supplementary files of this submission. This study will be registered under the National Institutes of Health ClinicalTrials.gov.

*Consent for publication:

Not applicable.

*Availability of data and material:

The datasets used and/or analyzed during the study will be available from the corresponding author upon reasonable request.

Trial Status:

Protocol: Version 2, May 1, 2019

The Delsys Trigno EMG machine has been ordered. The pharmacy has approved the intended capsaicin formula that will be used in the experiment. Participants will be recruited from June 2019 - November 2019

*Competing interests:

The authors declare that they have no competing interests.

*Funding:

This study is being conducted with no external funding.

*Authors’ Contribution:
All authors (VE, KM, DK) contributed to the study design; drafted, reviewed and finalized the study protocol; critically revised the manuscript and approved the final manuscript.

References


44. Westad C. Motor control of the upper trapezius. 2005

**Figures Legend:**

**Figure 1.** Flow chart of methods

**Figure 2.** Proposed experimental protocol timeline